Cargando…
Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women
Zoledronic acid is a nitrogen-containing, third-generation bisphosphonate that has recently been approved for the treatment of postmenopausal osteoporosis as an annual intravenous infusion. Zoledronic acid is an antiresorptive agent which has a high affinity for mineralized bone and especially for s...
Autores principales: | Lambrinoudaki, Irene, Vlachou, Sophia, Galapi, Fotini, Papadimitriou, Dimitra, Papadias, K |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2682377/ https://www.ncbi.nlm.nih.gov/pubmed/18982915 |
Ejemplares similares
-
Once-yearly zoledronic acid in hip fracture prevention
por: Demontiero, Oddom, et al.
Publicado: (2009) -
Cost-Effectiveness of Sequential Teriparatide/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2022) -
Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2022) -
Cost-Effectiveness of Zoledronic Acid Versus Oral Alendronate for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2020) -
Treatment of postmenopausal osteoporosis, patient perspectives – focus on once yearly zoledronic acid
por: Carmona, Raj, et al.
Publicado: (2009)